Senior GLP-1 Prescribing Rises 21% Under Medicare
CMS data shows GLP-1 prescribing among adults 65 and older climbed after the Medicare GLP-1 Bridge program launched in July 2026.
Updated on Nov. 2, 2026 in Weight Loss
Live Poll
Should Medicare cover weight-loss GLP-1 drugs for seniors at a low monthly cost?
GLP-1 prescribing among adults 65 and older increased nearly 21% between June and September 2026, following the launch of the Medicare GLP-1 Bridge program. CMS Administrator Dr. Mehmet Oz reported approximately 600,000 Bridge program sign-ups by August 31, 2026.
Why it matters
The Bridge program lets eligible beneficiaries pay $50 per month for brand-name weight-management GLP-1 drugs from outside Medicare Part D. Its results will inform whether weight-loss GLP-1s are integrated into standard Part D plans.
The CMS reported that prescribing rose about 21% among seniors while falling among younger adults over the same June-to-September window. Whether these shifts continue as the Bridge program runs through its planned 18-month period remains unknown.
The players
Dr. Mehmet Oz
Dr. Mehmet Oz is the Administrator of the Centers for Medicare & Medicaid Services, the federal agency overseeing Medicare.
Centers for Medicare & Medicaid Services (CMS)
The Centers for Medicare & Medicaid Services is the federal agency that administers Medicare and Medicaid and launched the GLP-1 Bridge program.
The details
The CMS launched the GLP-1 Bridge program on July 1, 2026, covering brand-name Wegovy, Zepbound, and Foundayo for weight management at $50 per month for eligible beneficiaries. Eligibility is based on body mass index and health conditions, and the program operates outside Medicare Part D, which bars Medicare from covering weight-management drugs.
Timeline
June 2026: Baseline month for measuring the senior GLP-1 prescribing increase.
July 1, 2026: CMS launched the GLP-1 Bridge program.
August 31, 2026: Bridge program reached approximately 600,000 sign-ups.
September 2026: Measurement period ended with the 21% senior increase recorded.
2027: The Bridge program is scheduled to end.
Big Picture
The Bridge program is being used as a test case after the CMS canceled the Medicare portion of the BALANCE Model when major payers declined to participate. The agency plans to use Bridge data to persuade Part D plan sponsors to join a revised version of that five-year pilot.
Eligible Medicare beneficiaries can access brand-name weight-management GLP-1s for $50 per month through the Bridge program. Seniors weighing whether to enroll should check eligibility based on body mass index and health conditions.
The takeaway
Medicare's Bridge program shows how federal coverage of weight-loss drugs can be tested outside existing benefit rules before being built into them. Its results will shape whether these drugs reach more patients through standard plans.
What happens next
The Bridge program is scheduled to end in 2027, and CMS plans to use its data to inform the BALANCE Model's potential revival.
Further reading
Explore more on Weight Loss coverage to see how GLP-1 drugs are changing treatment options and access.
Source note: This article includes information reported by TechTarget.
Live Poll
Should Medicare cover weight-loss GLP-1 drugs for seniors at a low monthly cost?
